Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Payables (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Payables readings, the most recent being $1.9 million for Q4 2025.

  • On a quarterly basis, Payables fell 60.11% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 60.11% decrease, with the full-year FY2025 number at $1.9 million, down 75.66% from a year prior.
  • Payables hit $1.9 million in Q4 2025 for Enanta Pharmaceuticals, down from $1.9 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $11.8 million in Q1 2023 to a low of $1.2 million in Q2 2022.
  • Median Payables over the past 5 years was $5.9 million (2021), compared with a mean of $6.1 million.
  • Biggest five-year swings in Payables: tumbled 78.88% in 2022 and later soared 537.11% in 2023.
  • Enanta Pharmaceuticals' Payables stood at $7.8 million in 2021, then tumbled by 44.5% to $4.4 million in 2022, then surged by 114.29% to $9.3 million in 2023, then plummeted by 49.32% to $4.7 million in 2024, then plummeted by 60.11% to $1.9 million in 2025.
  • The last three reported values for Payables were $1.9 million (Q4 2025), $1.9 million (Q3 2025), and $3.5 million (Q2 2025) per Business Quant data.